Physician profile
Barbra E Droddy
NPI 1740533280
$5,774.23
in general payments reported to CMS, 2019-2025
31 companies · $1,756 in 2025
The $1,756 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,296 · 2022: $774 · 2023: $564 · 2024: $1,385 · 2025: $1,756.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,459 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,459.04 |
| Education | $245.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $786.84 | 2021-2025 | |
| Genzyme Corporation | $751.48 | 2021-2025 | |
| Galderma Laboratories, L.P. | $683.65 | 2021-2025 | Nemluvio, Dysport |
| Janssen Biotech, INC. | $562.74 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $330.38 | 2021-2025 | |
| Ucb, INC. | $319.40 | 2021-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $234.49 | 2021-2024 | Arazlo, Cabtreo |
| Sun Pharmaceutical Industries INC. | $220.17 | 2021-2025 | Winlevi, Absorica Ld |
| E.R. Squibb & Sons, L.L.C. | $212.91 | 2023-2025 | Sotyktu |
| Amgen INC. | $177.37 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $149.30 | 2021-2022 | |
| Organogenesis INC. | $139.95 | 2021-2024 | Puraply |
| Organon LLC | $137.27 | 2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $124.20 | 2021-2025 | Dupixent |
| Leo Pharma INC. | $109.42 | 2021-2025 | Adbry |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $106.62 | 2021-2025 | Ebglyss |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Biofrontera INC. | $95.65 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Pfizer INC. | $77.30 | 2021-2023 | |
| Journey Medical Corporation | $72.68 | 2021-2023 | |
| Almirall LLC | $67.40 | 2021-2023 | Seysara |
| Mayne Pharma Commercial LLC | $58.12 | 2021-2024 | |
| Ani Pharmaceuticals, INC. | $53.11 | 2022-2023 | Apexicon E |
| Arcutis Biotherapeutics, INC. | $42.63 | 2025 | Zoryve |
| Dermavant Sciences, INC. | $37.77 | 2022-2024 | Vtama |
| Helsinn Therapeutics (U.S.), INC. | $35.33 | 2021-2022 | |
| Medimetriks Pharmaceuticals, INC. | $23.54 | 2022 | |
| Epi Health, LLC | $19.20 | 2022 | |
| Kerecis Limited | $18.33 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Vyne Pharmaceuticals INC. | $14.77 | 2021 | |
| Dermira, INC. | $12.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbra Droddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.